Board of Directors
Ron Cooper, Albireo’s first President and CEO, is a global P&L leader with a track record of growing businesses, brands and organizations in the U.S. and Europe. For over 25 years, Ron worked in five different countries and held positions of increasing responsibility in sales, marketing and general management with Bristol-Myers Squibb, culminating in his role as President of Europe where he was responsible for over 30 countries with sales exceeding $4.5 billion.
While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz® Sustiva® Sprycel® and Yervoy®. Ron has successfully completed more than a dozen business development deals, including the creation of the first single tablet HIV/AIDS regimen partnership. He is a graduate of St. Francis Xavier University in Canada.
-
David Chiswell, Ph.D. – ChairmanFormer CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP
-
Susan AlesinaVice President, National Business Development and Alliances, Boston Children’s Hospital
-
Ron CooperPresident and Chief Executive Officer
-
Habib DableFormer President and CEO, Acceleron Pharma; Currently Independent Director, Blueprint Medicines Corporation, and Venture Partner, RA Capital Management, L.P.
-
Michael Gutch, Ph.D.Chief Financial Officer, Noema Pharma
-
Stephanie S. Okey, M.S.Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company
-
Davey S. ScoonFormer CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors